Journal Basic Info

  • Impact Factor: 0.285**
  • H-Index: 6
  • ISSN: 2638-4558
  • DOI: 10.25107/2638-4558
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Neonatology
  •  Dermatology
  •  Otolaryngology
  •  Forensic and Legal Medicine
  •  Sexual Health
  •  Radiation Oncology
  •  Dentistry and Oral Medicine
  •  Surgery


Citation: Clin Case Rep Int. 2023;7(1):1593.DOI: 10.25107/2638-4558.1593

Relyvrio – For the Treatment of Amyotrophic Lateral  Sclerosis

Areeba I and Areeba I

Dow University of Health Sciences, Baba-E-Urdu Road, Pakistan
Karachi Medical and Dental College (KMDC) Block M, Pakistan

*Correspondance to: Areeba Ikram 

 PDF  Full Text Short Communication | Open Access




Drugs; Relyvrio; Amyotrophic lateral sclerosis; ALS; Lou Gehrig’s disease; FDA

Cite the Article:

Areeba I, Areeba I. Relyvrio – For the Treatment of Amyotrophic Lateral Sclerosis. Clin Case Rep Int. 2023; 7: 1593.

Search Our Journal

Journal Indexed In

Articles with Grants

ACE2 Gene Polymorphisms Associated with COVID-19 Infection Susceptibility to Cardiovascular Disease
 Abstract  PDF  Full Text
Gender Specificity in Obstructive Sleep Apnea and COVID-19: Putative Associations and Risk Factors
 Abstract  PDF  Full Text
View More...